PP-027 Preparation of topical amphotericin for oropharyngeal candidiasis in pregnant women
BackgroundOropharyngeal candidiasis is a common local infection usually caused by candida species. The primary treatment is usually nystatin or topical azoles but both drugs are known to be teratogenic, at least during first semester of pregnancy.PurposeThe aim was to present a new buccal formulatio...
Gespeichert in:
Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A213-A214 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A214 |
---|---|
container_issue | Suppl 1 |
container_start_page | A213 |
container_title | European journal of hospital pharmacy. Science and practice |
container_volume | 24 |
creator | García-Quintanilla, L Fernández-Ferreiro, A González-Barcia, M Ferro, I Zarra Lamas, MJ |
description | BackgroundOropharyngeal candidiasis is a common local infection usually caused by candida species. The primary treatment is usually nystatin or topical azoles but both drugs are known to be teratogenic, at least during first semester of pregnancy.PurposeThe aim was to present a new buccal formulation of amphotericin and determine its effectiveness in the treatment of oropharyngeal candidiasis in pregnant women.Material and methodsA bibliographic research was conducted to find the appropriate active substance that could be used during pregnancy and, as a result, amphotericin was chosen as it is considered the safest antifungal (it is classified in the B group of the FDA list) compared with other antifungal agents. Regarding excipients, we searched on Martindale, European Pharmacopoeia, etc, to find ones suitable that were compatible with the oropharyngeal mucosae.ResultsThe formulation was prepared from the amphotericin in powder form and dissolved in propylenglycol, Tween 80 and finally water. Strawberry extract was added. This topical solution had an amphotericin concentration of 25 mg/mL. The patient showed an improvement during treatment with amphotericin mouthwash, mentioning that the ulcers and little haemorrhages started to decrease after 3 days and that all symptoms remitted after 8 days. No relapses have occurred. The formulation was tolerated well without any adverse effects.ConclusionAmphotericin formulated as a mouthwash is an attractive alternative for oropharyngeal candidiasis in pregnant women.No conflict of interest |
doi_str_mv | 10.1136/ejhpharm-2017-000640.474 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552763264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4317855731</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1004-4b991fda7ed188e46427e23a4078ea616ef6d26409f310b5fe8bccf73a053a383</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMoWGr_Q8D11Lwmj6UUX1BwFroTQmYmaVM6yZiZIu7c-Ef9JWaounR1L9xz7uF8AECMlhhTfmV3235rUlcQhEWBEOIMLZlgJ2BGEBOFUpyd_u0lPweLYfA1KimVilE1Ay9VVSAivj4-q2R7k8zoY4DRwTH2vjF7aLp-G0ebfOMDdDHBmOKU-R42Np8bE1rfejP4AWZBn-wmmDDCt9jZcAHOnNkPdvEz5-D59uZpdV-sH-8eVtfrosYIsYLVSmHXGmFbLKVlnBFhCTUMCWkNx9w63pJcTTmKUV06K-umcYKaXMRQSefg8vi3T_H1YIdR7-IhhRypSVkSwWl2_6fCUtAJSYY6B_Soqrud7pPvclWNkZ5461_eeuKtj7x15k2_AQ1Udew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1873338911</pqid></control><display><type>article</type><title>PP-027 Preparation of topical amphotericin for oropharyngeal candidiasis in pregnant women</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>García-Quintanilla, L ; Fernández-Ferreiro, A ; González-Barcia, M ; Ferro, I Zarra ; Lamas, MJ</creator><creatorcontrib>García-Quintanilla, L ; Fernández-Ferreiro, A ; González-Barcia, M ; Ferro, I Zarra ; Lamas, MJ</creatorcontrib><description>BackgroundOropharyngeal candidiasis is a common local infection usually caused by candida species. The primary treatment is usually nystatin or topical azoles but both drugs are known to be teratogenic, at least during first semester of pregnancy.PurposeThe aim was to present a new buccal formulation of amphotericin and determine its effectiveness in the treatment of oropharyngeal candidiasis in pregnant women.Material and methodsA bibliographic research was conducted to find the appropriate active substance that could be used during pregnancy and, as a result, amphotericin was chosen as it is considered the safest antifungal (it is classified in the B group of the FDA list) compared with other antifungal agents. Regarding excipients, we searched on Martindale, European Pharmacopoeia, etc, to find ones suitable that were compatible with the oropharyngeal mucosae.ResultsThe formulation was prepared from the amphotericin in powder form and dissolved in propylenglycol, Tween 80 and finally water. Strawberry extract was added. This topical solution had an amphotericin concentration of 25 mg/mL. The patient showed an improvement during treatment with amphotericin mouthwash, mentioning that the ulcers and little haemorrhages started to decrease after 3 days and that all symptoms remitted after 8 days. No relapses have occurred. The formulation was tolerated well without any adverse effects.ConclusionAmphotericin formulated as a mouthwash is an attractive alternative for oropharyngeal candidiasis in pregnant women.No conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2017-000640.474</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Anemia ; Catheters ; Conflicts of interest ; Epistaxis ; High density polyethylenes ; Infections ; Iron ; Patients ; Pediatrics ; Pharmacy</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A213-A214</ispartof><rights>2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2017 (c) 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>García-Quintanilla, L</creatorcontrib><creatorcontrib>Fernández-Ferreiro, A</creatorcontrib><creatorcontrib>González-Barcia, M</creatorcontrib><creatorcontrib>Ferro, I Zarra</creatorcontrib><creatorcontrib>Lamas, MJ</creatorcontrib><title>PP-027 Preparation of topical amphotericin for oropharyngeal candidiasis in pregnant women</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundOropharyngeal candidiasis is a common local infection usually caused by candida species. The primary treatment is usually nystatin or topical azoles but both drugs are known to be teratogenic, at least during first semester of pregnancy.PurposeThe aim was to present a new buccal formulation of amphotericin and determine its effectiveness in the treatment of oropharyngeal candidiasis in pregnant women.Material and methodsA bibliographic research was conducted to find the appropriate active substance that could be used during pregnancy and, as a result, amphotericin was chosen as it is considered the safest antifungal (it is classified in the B group of the FDA list) compared with other antifungal agents. Regarding excipients, we searched on Martindale, European Pharmacopoeia, etc, to find ones suitable that were compatible with the oropharyngeal mucosae.ResultsThe formulation was prepared from the amphotericin in powder form and dissolved in propylenglycol, Tween 80 and finally water. Strawberry extract was added. This topical solution had an amphotericin concentration of 25 mg/mL. The patient showed an improvement during treatment with amphotericin mouthwash, mentioning that the ulcers and little haemorrhages started to decrease after 3 days and that all symptoms remitted after 8 days. No relapses have occurred. The formulation was tolerated well without any adverse effects.ConclusionAmphotericin formulated as a mouthwash is an attractive alternative for oropharyngeal candidiasis in pregnant women.No conflict of interest</description><subject>Anemia</subject><subject>Catheters</subject><subject>Conflicts of interest</subject><subject>Epistaxis</subject><subject>High density polyethylenes</subject><subject>Infections</subject><subject>Iron</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmacy</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kEtLAzEUhYMoWGr_Q8D11Lwmj6UUX1BwFroTQmYmaVM6yZiZIu7c-Ef9JWaounR1L9xz7uF8AECMlhhTfmV3235rUlcQhEWBEOIMLZlgJ2BGEBOFUpyd_u0lPweLYfA1KimVilE1Ay9VVSAivj4-q2R7k8zoY4DRwTH2vjF7aLp-G0ebfOMDdDHBmOKU-R42Np8bE1rfejP4AWZBn-wmmDDCt9jZcAHOnNkPdvEz5-D59uZpdV-sH-8eVtfrosYIsYLVSmHXGmFbLKVlnBFhCTUMCWkNx9w63pJcTTmKUV06K-umcYKaXMRQSefg8vi3T_H1YIdR7-IhhRypSVkSwWl2_6fCUtAJSYY6B_Soqrud7pPvclWNkZ5461_eeuKtj7x15k2_AQ1Udew</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>García-Quintanilla, L</creator><creator>Fernández-Ferreiro, A</creator><creator>González-Barcia, M</creator><creator>Ferro, I Zarra</creator><creator>Lamas, MJ</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201703</creationdate><title>PP-027 Preparation of topical amphotericin for oropharyngeal candidiasis in pregnant women</title><author>García-Quintanilla, L ; Fernández-Ferreiro, A ; González-Barcia, M ; Ferro, I Zarra ; Lamas, MJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1004-4b991fda7ed188e46427e23a4078ea616ef6d26409f310b5fe8bccf73a053a383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anemia</topic><topic>Catheters</topic><topic>Conflicts of interest</topic><topic>Epistaxis</topic><topic>High density polyethylenes</topic><topic>Infections</topic><topic>Iron</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmacy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Quintanilla, L</creatorcontrib><creatorcontrib>Fernández-Ferreiro, A</creatorcontrib><creatorcontrib>González-Barcia, M</creatorcontrib><creatorcontrib>Ferro, I Zarra</creatorcontrib><creatorcontrib>Lamas, MJ</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Quintanilla, L</au><au>Fernández-Ferreiro, A</au><au>González-Barcia, M</au><au>Ferro, I Zarra</au><au>Lamas, MJ</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PP-027 Preparation of topical amphotericin for oropharyngeal candidiasis in pregnant women</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2017-03</date><risdate>2017</risdate><volume>24</volume><issue>Suppl 1</issue><spage>A213</spage><epage>A214</epage><pages>A213-A214</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundOropharyngeal candidiasis is a common local infection usually caused by candida species. The primary treatment is usually nystatin or topical azoles but both drugs are known to be teratogenic, at least during first semester of pregnancy.PurposeThe aim was to present a new buccal formulation of amphotericin and determine its effectiveness in the treatment of oropharyngeal candidiasis in pregnant women.Material and methodsA bibliographic research was conducted to find the appropriate active substance that could be used during pregnancy and, as a result, amphotericin was chosen as it is considered the safest antifungal (it is classified in the B group of the FDA list) compared with other antifungal agents. Regarding excipients, we searched on Martindale, European Pharmacopoeia, etc, to find ones suitable that were compatible with the oropharyngeal mucosae.ResultsThe formulation was prepared from the amphotericin in powder form and dissolved in propylenglycol, Tween 80 and finally water. Strawberry extract was added. This topical solution had an amphotericin concentration of 25 mg/mL. The patient showed an improvement during treatment with amphotericin mouthwash, mentioning that the ulcers and little haemorrhages started to decrease after 3 days and that all symptoms remitted after 8 days. No relapses have occurred. The formulation was tolerated well without any adverse effects.ConclusionAmphotericin formulated as a mouthwash is an attractive alternative for oropharyngeal candidiasis in pregnant women.No conflict of interest</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2017-000640.474</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9956 |
ispartof | European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A213-A214 |
issn | 2047-9956 2047-9964 |
language | eng |
recordid | cdi_proquest_journals_2552763264 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Anemia Catheters Conflicts of interest Epistaxis High density polyethylenes Infections Iron Patients Pediatrics Pharmacy |
title | PP-027 Preparation of topical amphotericin for oropharyngeal candidiasis in pregnant women |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T10%3A57%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PP-027%E2%80%85Preparation%20of%20topical%20amphotericin%20for%20oropharyngeal%20candidiasis%20in%20pregnant%20women&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Garc%C3%ADa-Quintanilla,%20L&rft.date=2017-03&rft.volume=24&rft.issue=Suppl%201&rft.spage=A213&rft.epage=A214&rft.pages=A213-A214&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2017-000640.474&rft_dat=%3Cproquest_bmj_p%3E4317855731%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1873338911&rft_id=info:pmid/&rfr_iscdi=true |